iShares International Treasury Bond ETF vs Medtronic PLC — how do they compare? iShares International Treasury Bond ETF trades at $39.75 (market cap $1.30B), while Medtronic PLC trades at $89.13 (market cap $112.24B). The key difference: Medtronic PLC is far larger — about 86.3× iShares International Treasury Bond ETF's market cap, and Medtronic PLC pays a 3.28% dividend while iShares International Treasury Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares International Treasury Bond ETF for 92 Days and Medtronic PLC for 63 Days on average.
| IGOV | MDT | |
|---|---|---|
Market Cap | $1.30B | $112.24B |
Volume | 693,740 | 105,663,236 |
Sector | Fixed Income | Health |
52-Week High | $42.99 | $105.35 |
52-Week Low | $39.65 | $73.75 |
Typical Hold Time | 92 Days | 63 Days |
Enterprise Value | — | $131.58B |
Dividend Yield | — | 3.28% |
Signals from Pluang's Aura AI — not financial advice
IGOV trades at $39.75 with minimal daily movement (+0.13%). Technical indicators show a bearish bias with moving averages signaling caution, though oscillators remain neutral. The stock faces significant resistance at $40 across multiple levels. Financial ratios are unavailable in current data, limiting fundamental assessment.
The stock's outlook remains cautious due to technical weakness and limited fundamental visibility. Rising bond yields create macroeconomic headwinds for equities, though inverse Treasury ETFs may benefit. Investors require updated financial disclosures to properly evaluate valuation and growth prospects amid current market volatility.
Medtronic (MDT) trades at $85.51, down 1.81% on the day, with the stock showing bearish technical signals despite strong fundamental performance. The company has beaten earnings expectations for three consecutive quarters, maintains a healthy 13.93% net income margin, and offers a solid 3.2% dividend yield with 49 consecutive years of dividend growth. Recent positive developments include FDA clearances for new medical technologies and raised full-year guidance.
MDT presents a compelling value opportunity with analyst consensus pointing to 14% upside to the $97.80 price target. The stock's current valuation multiples (P/E 21.61, P/S 3.01) appear reasonable given the company's stable revenue growth and strong cash flow generation. Key risks include increasing debt levels and competitive pressures in the medical device sector, but the company's dividend aristocrat status and improving operational performance support a positive long-term outlook.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
The fund will invest at least 80% of its assets in the component securities of the underlying index and will invest at least 90% of its assets in fixed income securities included in the underlying index. The underlying index measures the performance of fixed-rate, local currency, investment-grade, sovereign bonds from certain developed markets. The fund is non-diversified.
Read more on IGOV →One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →